Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial

According to data from the randomized, phase II MAJIC-PV trial comparing ruxolitinib versus best available therapy (BAT) in patients with polycythemia vera resistant/intolerant to hydroxycarbamide, duration of complete response (CR) was superior for the ruxolitinib arm (HR, 0.38; 95% CI, 0.24-0.61; P < .001). Event-free survival was superior for patients with a CR within 1 year (HR, 0.41; 95% CI, 0.21-0.78; P = .01), as well as for those on ruxolitinib (HR, 0.58; 95% CI, 0.35-0.94; P = .03). Patients treated with ruxolitinib more frequently achieved a molecular response, and molecular response was associated with improved outcomes (PFS: P = .001; EFS: P = .001; OS: P = .01).